Evaluation of HER2DX Assay on Treatment Decisions in Patients With Early Stage HER2+ Breast Cancer: the HER2BREASTDX
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorEuropean Institute of Oncology
About this trial
To prospectively evaluate the impact of HER2DX on the decision-making processes of the treating physicians and especially among the routine multidisciplinary tumour board, in defining type and setting of systemic therapy administration in patients with stage I-III HER2+ BC, and the degree of clinician's confidence in the treatment recommendation.
Eligibility criteria
Qualifiers
Patients ≥ 18 years of age;
Histologically confirmed HER2+ breast cancer;
Stage I-III breast cancer without evidence of distant metastases;
Being candidate to neoadjuvant/adjuvant therapy and locoregional treatment (surgery +/- radiotherapy);
Disqualifiers
HER2- BC;
Stage IV breast cancer;
Lack of informed consent because of patient's incapable of discernment or unwilling to participate;
Trial design
Treatments tested in this trial
- Neoadjuvant standard treatment for HER2+
- Adjuvant standard treatment for HER2+
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov